A Phase IV, Randomized, Double-Blind, Crossover Study to Compare the Clinical Safety and Efficacy of AbobotulinumtoxinA and OnabotulinumtoxinA in Adult Upper Limb Spasticity - PubMed
3 hours ago
- #clinical trial
- #spasticity
- #botulinum toxin
- The study compared the safety and efficacy of abobotulinumtoxinA (aboBoNT-A) and onabotulinumtoxinA (onaBoNT-A) for upper limb spasticity (ULS).
- It was a phase IV, randomized, double-blind, crossover study involving 464 patients at 72 sites.
- The adjusted rate of treatment-emergent adverse events (TEAEs) for aboBoNT-A (20.3%) was non-inferior to onaBoNT-A (23.0%).
- The adjusted mean duration of response was 99.3 days for aboBoNT-A and 96.3 days for onaBoNT-A, with a difference of 3.0 days favoring aboBoNT-A.
- Longer duration of response with aboBoNT-A was observed across most subgroups during fixed-interval follow-up.
- These findings may support informed therapeutic decision-making for managing adult upper limb spasticity.